Funding for this research was provided by:
Text and Data Mining valid from 2020-03-12
Received: 22 December 2019
Accepted: 2 March 2020
First Online: 12 March 2020
Ethics approval and consent to participate
: The original PINNACLE-1, − 2, and − 4 studies were conducted in accordance with the amended Declaration of Helsinki and approved by local institutional review boards (details previously published) [CitationRef removed, CitationRef removed]. Patients provided signed informed consent prior to screening.
: Not applicable.
: BJL declares research grants from AstraZeneca, Boehringer Ingelheim, Chiesi, and Janssen. BJL declares speaker fees from AstraZeneca, Boehringer Ingelheim, and Teva. BJL declares consulting fees from Boehringer Ingelheim, Chiesi, Sandoz, Cipla, Dr. Reddys, and Lupin. BJL declares advisory board fees from Teva. JZ declares advisory board fees from AstraZeneca, Boehringer Ingelheim and grants from GlaxoSmithKline. MJ, PNA, and LW are employees of AstraZeneca. MJ is a shareholder of AstraZeneca. The authors declare that they have no competing interests.